This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: direct oral anticoagulant (DOAC)

January 2022 Br J Cardiol 2022;29:26–30 doi:10.5837/bjc.2022.001

New agents for DOAC reversal: a practical management review

Katie White, Uzma Faruqi, Alexander (Ander) T Cohen

Abstract

Introduction Anticoagulation is utilised in the management of venous thromboembolism and to prevent thrombotic complications in patients with cardiac comorbidities, e.g. atrial fibrillation (AF), valvular heart disease, congenital heart disease, and other indications. Direct oral anticoagulants (DOACs), also known as NOACs (non-vitamin K antagonist oral anticoagulants), have shown superior efficacy, safety, adherence and tolerability over traditional anticoagulants, such as vitamin K antagonists and low-molecular weight heparins, and this has resulted in a paradigm shift with DOACs as the preferred options for most patients with thrombotic d

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now